



## Statin Therapy for patients With Diabetes (SPD)

### SPD Measure Description<sup>1</sup>

Assesses the percentage of members 40–75 years of age with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria. Two rates are reported:

1. Received Statin Therapy: Members who were dispensed at least one statin medication of any intensity.
2. Statin Adherence 80%: Members who remained on a statin medication of any intensity for at least 80% of the treatment period.

### Why is SPD Important?<sup>1</sup>

Diabetes increases the risk of cardiovascular disease, with patients facing higher mortality rates after onset. Statins are widely used to lower cholesterol and reduce cardiovascular risk, especially in diabetes management. Guidelines from the ADA and ACC/AHA recommend statins for primary prevention based on age and risk factors. Studies strongly support statin use for both primary and secondary prevention in patients with type 2 diabetes.

### Best Practices

- ✓ Educate on the importance of complying with statin therapy during every communication.
- ✓ Simplify the medication regimen by using once-daily dosing, if possible.
- ✓ Listen to members' concerns and make them an active part of shared-decision making.
- ✓ Routinely arrange the next appointment for consistent follow-up and monitoring.

Numerator Compliance<sup>2</sup>

**Rate 1: Received Statin Therapy** - The number of members who had at least one dispensing event for a high-intensity or moderate-intensity statin medication during the measurement year.

**Rate 2: Statin Adherence 80%** - The number of members who achieved a proportions of days covered of at least 80% during the treatment period.

Refer to the next page for the list of medications.

Data Collection Method<sup>2</sup>

Administrative (Claims)



Trillium Percentages/NCQA National Averages<sup>1</sup>

SPD	Measurement Year	Trillium	NCQA National Average
Rate 1: Received Statin Therapy	2023	-	63.83
	2022	-	-
Rate 2: Statin Adherence 80%	2023	-	67.41
	2022	-	-

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

<sup>1</sup> Source: <https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/>

<sup>2</sup> Source: HEDIS MY 2025 Tech Specs Manual Vol. 2

SPC Numerator Medications<sup>2</sup>

Description	Prescription	
High-intensity statin therapy	Amlodipine-atorvastatin 40-80 mg Atorvastatin 40-80 mg Ezetimibe-simvastatin 80 mg	Rosuvastatin 20-40 mg Simvastatin 80 mg
Moderate-intensity statin therapy	Amlodipine-atorvastatin 10-20 mg Atorvastatin 10-20 mg Ezetimibe-simvastatin 20-40 mg Fluvastatin 40-80 mg Lovastatin 40-60 mg	Pitavastatin 1-4 mg Pravastatin 40-80 mg Rosuvastatin 5-10 mg Simvastatin 20-40 mg
Low-intensity statin therapy	Ezetimibe-simvastatin 10 mg Fluvastatin 20 mg Lovastatin 10-20 mg	Pravastatin 10–20 mg Simvastatin 5-10 mg

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

<sup>1</sup> Source: <https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/>

<sup>2</sup> Source: HEDIS MY 2025 Tech Specs Manual Vol. 2